Organization
Rheumatology and Immunotherapy Center, Franklin, United States of America
3 abstracts
Abstract
APREMILAST MONOTHERAPY AS THE FIRST SYSTEMIC TREATMENT IN DMARD-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 3-YEAR TREATMENT RESULTS Org: Celgene Corporation, West Tennessee Research Institute, Rheumatology and Immunotherapy Center, Franklin, United States of America, Altoona Center for Clinical Research, Duncansville, United States of America, Combined Rheumatology Practice, Kogarah,
Abstract
A COMPARATIVE ANALYSIS OF UPADACITINIB MONOTHERAPY AND UPADACITINIB COMBINATION THERAPY FOR THE TREATMENT OF RHEUMATOID ARTHRITIS FROM TWO PHASE 3 TRIALSOrg: University of Leeds & NIHR Biomedical Research Centre, Leeds, United Kingdom, Rheumatology and Immunotherapy Center, Franklin, United States of America, Kantonsspital St Gallen, St Gallen, Switzerland, Rheumatology, Great Lakes Clinical Trials, Chicago, United States of America, AbbVie Inc., North Chicago, United States of America,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL Org: Celgene Corporation, University Hospital Southampton NHS Foundation Trust, Rheumatology and Immunotherapy Center, Franklin, United States of America, University of Sheffield, Altoona Center for Clinical Research, Duncansville, United States of America,